GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stayble Therapeutics AB (OSTO:STABL) » Definitions » EV-to-EBITDA

Stayble Therapeutics AB (OSTO:STABL) EV-to-EBITDA : 0.62 (As of May. 14, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Stayble Therapeutics AB EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Stayble Therapeutics AB's enterprise value is kr-13.71 Mil. Stayble Therapeutics AB's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was kr-22.08 Mil. Therefore, Stayble Therapeutics AB's EV-to-EBITDA for today is 0.62.

The historical rank and industry rank for Stayble Therapeutics AB's EV-to-EBITDA or its related term are showing as below:

OSTO:STABL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -9.72   Med: 0   Max: 1.51
Current: 0.62

During the past 7 years, the highest EV-to-EBITDA of Stayble Therapeutics AB was 1.51. The lowest was -9.72. And the median was 0.00.

OSTO:STABL's EV-to-EBITDA is ranked better than
74.95% of 463 companies
in the Biotechnology industry
Industry Median: 9.32 vs OSTO:STABL: 0.62

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-14), Stayble Therapeutics AB's stock price is kr0.239. Stayble Therapeutics AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was kr-1.070. Therefore, Stayble Therapeutics AB's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Stayble Therapeutics AB EV-to-EBITDA Historical Data

The historical data trend for Stayble Therapeutics AB's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stayble Therapeutics AB EV-to-EBITDA Chart

Stayble Therapeutics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBITDA
Get a 7-Day Free Trial - - -3.80 -4.16 -1.74

Stayble Therapeutics AB Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.76 -1.74 -0.91 -1.22 -6.06

Competitive Comparison of Stayble Therapeutics AB's EV-to-EBITDA

For the Biotechnology subindustry, Stayble Therapeutics AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Stayble Therapeutics AB's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Stayble Therapeutics AB's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Stayble Therapeutics AB's EV-to-EBITDA falls into.



Stayble Therapeutics AB EV-to-EBITDA Calculation

Stayble Therapeutics AB's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=-13.712/-22.084
=0.62

Stayble Therapeutics AB's current Enterprise Value is kr-13.71 Mil.
Stayble Therapeutics AB's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-22.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Stayble Therapeutics AB  (OSTO:STABL) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Stayble Therapeutics AB's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.239/-1.070
=At Loss

Stayble Therapeutics AB's share price for today is kr0.239.
Stayble Therapeutics AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-1.070.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Stayble Therapeutics AB EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Stayble Therapeutics AB's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Stayble Therapeutics AB (OSTO:STABL) Business Description

Traded in Other Exchanges
Address
Medicinaregatan 8a, Gothenburg, SWE, SE-413 90
Stayble Therapeutics AB is a clinical-stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and analgesics. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. The company's injection treatment, STA363, is expected to correct the underlying cause of disc-related low back pain by affecting the two main causative factors namely instability of the disc and prevention of leakage of inflammatory mediators from the disc center.

Stayble Therapeutics AB (OSTO:STABL) Headlines

No Headlines